Sign up
Tech Capital

Amphion Innovations trims its stake in Motif Bio

Life sciences and technology incubator Amphion Innovations recently rolled over £6.56mln of promissory notes due in December 2018 for a year.
US dollars
One-third of the proceeds from the sale will be retained for working capital

Amphion Innovations PLC (LON:AMP) has reduced its stake in partner company Motif Bio PLC (LON:MTFB, NASDAQ:MTFB) to 7.88%.

It sold 1.83mln shares in Motif, generating US$144,000, two-thirds of which will go to effect partial repayment of the loan facility it took out in mid-2014.

READ: Motif Bio to manage cash aggressively after making loan repayment

Prior to the sale, Amphion’s stake in Motif Bio, which is developing iclaprim, a next-generation antibiotic, was 8.51%.


Why Invest In Amphion Innovations PLC? Read More Here

Register here to be notified of future AMP Company articles
View full AMP profile View Profile
View All

Related Articles

Internet of things
In an update in January, the company said that revenue for the year just ended would be at the top end of its guidance range at around US$427mln

© tech Capital 2019

Tech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed tech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Tech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Technology market.